NCT07150377View on ClinicalTrials.gov

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 24, 2025

Primary Completion Date

August 24, 2026

Study Completion Date

August 24, 2028

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

First-line Cohort

Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd

DRUG

Second-line Cohort

Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd

All Listed Sponsors
lead

The Second Affiliated Hospital of Shandong First Medical University

OTHER